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Introduction
Cytochrome P450 (CYP) is an enzyme superfamily that 
catalyses the oxidation of a wide variety of endogenous 
and exogenous substrates. Over the years, various authors 
have discovered that the major epoxygenase enzymes of 
arachidonic acid belong to the CYP2 subfamily, namely 
CYP2C and CYP2J (Daikh et al. 1994; Wu at al. 1996). In 
particular, CYP2J members produce cis-epoxyeicosa-
trienoic acids (EETs) and mid-chain cis–trans-conjugated 
dienols (HETEs), and ω-terminal alcohols (Scarborough 
et al. 1999). These compounds play an important role in 
many endogenous functions such as the regulation of 
hormone secretion, vascular tone (Campbell & Harder 
1999), and renal microtubular excretion (Wu et al. 
1997). Moreover, a perturbation of the arachidonic acid 
metabolism and eicosanoid biosynthesis seem to be 
involved in numerous pathophysiological states, such as 
vascular disease, neoplastic phenotype (Jiang et al. 2005), 
inflammation (Spiecker & Liao 2005), the alteration of 
hormonal secretion (Capdevilla et al. 2000), and the fail-
ure of renal microtubular filtration (Wu et al. 1997). Other 
important compounds are substrates of CYP2J such as 
all-trans-retinal that is oxidized into all-trans-retinoic 
acid. The importance of this oxidation derives from the 
involvement of this metabolite in embryo development 
during pregnancy. In fact, retinoic acid and its metabo-
lites are responsible for accelerated organ development 
and maturation (Zhang et al. 1998; Wang et al. 2007). In 
addition to their role in the metabolism of endogenous 
compounds, CYP2J enzymes are active in oxidation 
of xenobiotics such as aminopyrine, benzphetamine, 
diclofenac, ebastine, and astemizole (Scarborough et al. 
1999; Hashizume et al. 2002; Matsumoto et al. 2003).
Many members of this subfamily are described in 
mammals: one in rabbit (CYP2J1) (Kikuta et al. 1991), 
two (CYP2J3, CYP2J4) in rat (Wu et al. 1997; Zhang 
et al. 1997), four (CYP2J5, CYP2J6, CYP2J9, CYP2J11) 
Xenobiotica
Xenobiotica, 2010; 40(2): 109–118
2010
40
2
109
118
Address for Correspondence: V. Longo, Istituto di Biologia e Biotecnologia Agraria, CNR, Via Moruzzi, 1, I-56100, Pisa, Italy. Tel: 39-0503152690. Fax: 
39-0503153328. E-mail: v.longo@ibba.cnr.it
07 September 2009
12 October 2009
13 October 2009
0049-8254
1366-5928
© 2010 Informa UK Ltd
10.3109/00498250903410590
R E S E A R C H  A R T I C L E
Molecular cloning and enzymatic characterization of 
sheep CYP2J
A. Messina1, S. Nencioni1, P. G. Gervasi1, K. H. Gotlinger3, M. L. Schwartzman3, and V. Longo2
1Istituto di Fisiologia Clinica, CNR, Pisa, Italy, 2Istituto di Biologia e Biotecnologia Agraria, CNR, Pisa, Italy, and 
3Department of Pharmacology, New York Medical College, Vahalla, NY, USA 
Abstract
1.  Cytochrome P450 (CYP) 2Js have been studied in various mammals, but not in sheep, as an animal model 
used to test veterinary drug metabolism.
2.  Sheep CYP2J was cloned from liver messenger RNA (mRNA) by RACE. The cDNA, after modification at its 
N- and C-terminals, was expressed in Escherichia coli and the sheep CYP2J protein, purified by chroma-
tography, was 80% homologous to human and monkey CYP2J2.
3.  Reverse transcriptase-polymerase chain reaction (RT-PCR) experiments showed that CYP2J mRNA was 
expressed in liver, cortex, respiratory and olfactory mucosa, heart, bronchi, lung, spleen, small intestine 
and kidney.
4.  The purified enzyme was catalytically active towards aminopyrine, all-trans-retinoic acid, and particularly 
arachidonic acid forming 20-HETE, 19-HETE, and 18-HETE (about 86% of the total) and 14,15-, 11,12-, 8,9-, 
and 5,6-EETs (cis-epoxyeicosatrienoic acids; about 14% of total), with a regioselectivity similar to that 
shown by the mammalian CYP2J2s.
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in mouse (Ma et al. 1999; Scarborough et al. 1999; Qu 
et al. 2001), and only one (CYP2J2) in human, monkeys, 
dog, and Bos taurus (see http://drnelson.utmem.edu/
cytochromeP450.html). The expression of P4502J is 
documented in many tissues such as liver, kidney, heart, 
intestine, lung, and brain and the biochemical features 
are described using purified recombinant enzymes. 
However, the enzymatic properties of CYP2Js and their 
tissue-specific distribution differ across the species 
(Scarborough et al. 1999). Thus, it appears useful to 
investigate the feature of CYP2J in a large animal such as 
sheep. Sheep is an animal model used to test veterinary 
drug metabolism (Ioannides 2006) and to study vascular 
process such as heart blood circulation and ductus arte-
riosus closure at birth (Coceani et al. 1996).
The aim of this work was to isolate a sheep liver cDNA 
which encodes CYP2J, expresses this enzyme in the 
Escherichia coli heterologous system, purifies it, and, 
subsequently, characterizes its catalytic activities.
Materials and methods
Materials
Tripure isolation reagent, restriction endonuclease NdeI 
and SalI, T4 DNA Ligase were obtained from Roche 
Molecular Biochemicals (Indianapolis, IA, USA). DNA 
primers were purchased from Sigma-Aldrich Genomics 
(Milan, Italy). Gene Racer Kit, Thermo Script III Reverse 
Transcriptase, Platinum Pfx Taq polymerase, pCR4Blunt 
vector, Ni-NTA Agarose resin, 3 M imidazole solution 
were obtain from Invitrogen Life Technologies (Carlsbad, 
CA, USA). β-Nicotinamide adenine dinucleotide phos-
phate, reduced form (NADPH), ampicillin, isopropyl-
β-D-thiogalactopyranoside (IPTG), δ-aminolevulenic 
acid 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfate (CHAPS), dilauroyl-L-3-phosphatidyl 
choline (DLPC), ethyldiaminotetraacetic acid (EDTA), 
dithiothreitol (DTT), glycerol, arachidonic acid, all-trans 
retinal, all-trans retinoic acid, 7-ethoxycoumarin, astemi-
zole, diclofenac, aniline, aminopyrine and peroxidase-
conjugated anti-rabbit immunoglobulin G (IgG) were 
from Sigma-Aldrich (St. Louis, MO, USA). Master Mix 
PCR, Wizard® Plus SV gel extraction kit and Wizard® Plus 
SV MiniPrepsDNA Purification System were purchased 
from Promega (Madison, WI, USA). Testosterone and its 
metabolites were obtained as previously reported (Longo 
et al. 1991). The ECL kit was purchased from Amersham 
(Amersham, UK). 8,9-EET-d8 (internal standard) was 
obtained from Biomol International (Exeter, UK).
Animals
Tissues of untreated sheep (Apuana) weighing 30–40 kg 
were obtained from San Pietro a Grado breeding section 
of the Veterinary University of Pisa (Pisa, Italy). All tissues 
were stored at −80°C until preparation of total RNA.
RNA isolation and sheep CYP2J cloning
Total RNA from sheep liver was isolated with Tripure 
Isolation Reagent and modified by a Gene Racer Kit 
according with the manufacturer’s instructions. First, 
a CYP2J cDNA central fragment of 353 bp was cloned 
with two primers S and AS (Table 1) obtained by a multi-
alignment of rat, rabbit, human, dog, and Bos taurus 
sequences of CYP2J present in Gene Bank database 
(Table 1). Polymerase chain reaction (PCR) was per-
formed using 40 cycles including 30 s at 94°C, 30 s at 50°C, 
and 1 min at 68°C and a proof-reading Platinum Pfx Taq 
Polymerase according to the Invitrogen Gene Racer Kit. 
The full-length cDNA was obtained employing for the 
isolation of the missing 5′-end, the two reverse primers: 
Table 1. Oligonucleotide sequence and size of fragment obtained with PCR primers mix.
CYP2J fragment   
 S 5’-CCC TCA XTT CAA GAT CAA CA-3’  
 AS 5’-GCA GAT GAG GTT TTC TTC AT-3’ 353 bp
Gene Racer Primers   
 5’GRP 5’-GAA TAG CCT TTG GTG TGG ACC CGG A-3’  
 5’GNP 5’-TAG GTG ACC TCA TCC AGC AGC CTC A-3’ 700 bp
 3’GRP 5’ TTG GGG AGC GGT TTG ACT ACC AGG A-3’  
 3’GNP 5’-TCC GGG TCC ACA CCA AAG GCT ATT C-3’ 1300 bp
CYP2J Modification Primers   
 MALLLV 5’-GCCATGGCTCTGTTATTAGCAGTTTTTGCGGGCTGCCCTCTGG-3’
 RSP 5’-CTTTGCTCTTTCCATATGTG-3’ 454 bp
 FSP 5’ -CACATATGGAAAGAGCAAAG-3’  
 His-tag 5’-CAGCTGTCAGTGATGGTGATGGGCCCGAGGAACAGC-3’ 1100 bp
ß-actin   
 S 5’-GCTCGTCGTCGACAACGGCTC-3’  
 AS 5’-CAAACATGATCTGGGTCATCTTCTC-3’ 353 bp
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5′GRP and 5′GNP (Table 1); and for the isolation of the 
missing 3′-end, the following two forward primers: 3′GRP 
and 3′GNP (Table 1). The Gene Racer PCR products were 
sub-cloned in pCR4Blunt vector and sequenced by BMR 
Genomics Sequencing Core service (Padua, Italy). The 
CYP2J homologies were performed with NCBI-BLAST 
database.
CYP2J subcloning in pCWOri+
Heterologous expression of CYP2J required its trunca-
tion in two parts as the gene contains an internal NdeI 
site. This expedience was performed since the expres-
sion vector used in the studies was the pCWOri+ vector 
that requires the introduction of the NdeI site in the 
N-terminal of the CYP gene to establish a right coding 
frame as described by other workers (Guo et al. 1994; 
Gillam et al. 1995). Furthermore, the nucleotide sequence 
encoding its wild-type N-terminal region was changed to 
include the MALLLV amino acids sequence and the NdeI 
site, as previously reported (Fisher et al. 1992). These two 
modifications required the truncation of sheep CYP2J 
nucleotides sequence in two fragments, because sheep 
CYP2J cDNA contains an internal NdeI site. The cloning 
scheme was presented in Figure 1.
N-terminal modification was introduced with a 
PCR amplification on native the CYP2J sequence using 
MALLLV and RSP primers and 40 PCR cycles including 
30 s at 94°C, 30 s at 55°C, and 45 s at 68°C. The 540 bp frag-
ment was cloned in pCR4Blunt vector and sequenced by 
BMR Genomics Sequencing Core service (Padua, Italy).
The nucleotide sequence encoding a wild-type 
C-terminal region is changed to include the His-tag 
sequence (4 His) to facilitate protein purification and a 
SalI restriction site for the cloning in pCWOri+ vector, as 
previously reported (Guo et al. 1994; Gillam et al. 1995). 
The used strategy and the PCR program were the same for 
the N-terminal modification but using FSP and His-tag 
primers (Table 1). The 1100 pb fragment was cloned in 
pCR4Blunt vector and sequenced by BMR.
Genomics
Finally, recombinant sheep CYP2J cDNA was recom-
posed in pCWOri+ vector and introduced in E. coli cells.
Expression of sheep CYP2J pCWOri+ plasmid
Plasmid was transformed in E. coli DH5α cells. A single 
resistant colony of DH5α cells transformed with the 
plasmid was grown overnight a 37°C in Luria–Bertani 
medium containing 100 µg ml−1 of ampicillin. A 10 ml 
aliquot of Luria–Bertani pre-culture was inoculated into 
1 L of Terrific Broth (TB). The TB medium was supple-
mented with ampicillin (100 µg ml−1), 1 mM thiamine, 
0.5 mM δ-aminolevulenic acid and trace elements. The 
culture was incubated at 30°C in a bath with a vigorous 
shaking; after 2.5 h, isopropyl β-D-thiogalactopyranoside 
(1 mM) was added to induce the tac promoter and cul-
ture was maintained 24 h for the expression of sheep 
CYP2J. Cells were kept at −20°C for 1 h and centrifuged 
at 5000g for 15 min. The TB was discarded and bacterial 
pellets were resuspended in 100 mM Tris-acetate buffer 
(pH 7.6) containing 500 mM sucrose and 0.5 mM EDTA 
(15 ml buffer g−1). Lysozyme was added (to 0.3 mg g−1 cells) 
and the suspension was diluted two-fold with water. After 
gentle mixing at 4°C for 30 min, the resulting spheroplasts 
were collected by centrifugation at 10 000g for 15 min and 
the pellet was resuspended in 100 mM phosphate buffer 
(pH 7.4) containing 20% glycerol, 6 mM magnesium 
acetate, 0.1 mM DTT and protease inhibitors (0.2 mM 
phenylmethanesulphonyl fluoride (PMSF), 1 µg ml−1 
each of aprotinin, leupeptin, bestatin). Spheroplasts were 
lysed by sonication three times with cycles of 15 s ON and 
5 s OFF. The resulting lysate was centrifuged at 10 000g for 
20 min and the supernatant was collected and centrifuged 
at 100 000g for 2.5 h. The soluble fraction was discarded 
and the red–orange membrane pellet was resuspended 
and used for CYP2J purification.
Protein purification
Membranes were solubilized for 2 h in potassium phos-
phate buffer 300 mM (pH 7.4) containing 20% glycerol 
(v/v) and 1% CHAPS. The solution was centrifuged at 
100 000g for 30 min to remove the insoluble fraction. 
The supernatant containing His-tagged sheep CYP2J 
was purified by an affinity chromatography column 
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Figure 1. Scheme of sheep CYP2J subcloning in pCWOri vector.
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containing 2 ml of Ni-NTA Agarose resin. The column 
was washed with 30 ml of 300 mM potassium phosphate 
buffer (pH 7.4) containing 20% glycerol (v/v), 1% CHAPS 
and 20 mM imidazole. Red-coloured fraction containing 
CYP2J was eluted by 300 mM potassium phosphate buffer 
(pH 7.4) containing 20% glycerol (v/v) and 1% CHAPS 
and 200 mM imidazole. The removal of imidazole and 
CHAPS from CYP2J solution was achieved by dialysis in 
100 vols of 100 mM potassium phosphate buffer (pH 7.4) 
containing 0.1 mM EDTA, 0.1 mM DTT and 20% glycerol 
(v/v) (Wu et al. 2007). The purity was assessed by sodium 
dodecylsulphate (SDS) (7.5% w/v)-PAGE, according to the 
method of Laemmli (1970), and by Western blot analysis 
(Towbin et al. 1979) performed using anti-human CYP2J2 
antibodies. Protein content was measured by method of 
Lowry et al. (1951).
RT-PCR analysis for CYP2J mRNA distribution
Total RNA was isolated from cortex, respiratory mucosa, 
olfactory mucosa, aorta, pulmonary artery, heart, bron-
chi, lung, liver, spleen, small intestine and kidney. Total 
RNA (1 µg) integrity was checked by a formaldehyde-
agarose gel. Then 2.5 µg were reversed transcribed using 
oligo-dT primers and cDNAs obtained were used for 
RT-PCR with a program and primers for 378 bp fragment 
previously described (Table 1). The PCR products were 
analysed on agarose gel, purified and sequenced. β-Actin 
was used as housekeeping gene to test the cDNA quality 
(Table 1).
Immunoblot analysis
Tissue microsomes were subjected to SDS-PAGE using 
the method of Laemmli (1970) in a Bio-Rad mini Protean 
II apparatus. Proteins were transferred from slab gel to 
nitrocellulose filters following the method of Towbin et al. 
(1979). Immunodetection was performed with anti-hu-
man CYP2J2 polyclonal antibodies (generously supplied 
by Dr Zeldin). Immunoreactive proteins were visualized 
with a chemiluminescence reaction kit (Amersham).
Enzymatic assays
CYP content was determined using Omura & Sato (1964) 
method. Enzyme activities of the purified CYP were 
performed in a reconstituted system containing 100 
pmol of CYP2J, 200 pmol of NADPH-cytochrome P450 
reductase, 30 µg of lipids (DLPC) and 1 mM NADPH 
or NADPH-regenerating system which had been pre-
incubated for 30 min at room temperature (Reed et al. 
2006). Then, after the addition of G6PDH (1 U) and the 
substrate in a volume of 1 ml, the complete system was 
generally incubated for 30 min at 37°C. Hydroxylation of 
aniline and demethylation of aminopyrine were assayed 
according to Ko et al. (1987) and Tu & Yang (1983), 
respectively. Ethoxycumarin-O-deethylase was assayed 
by the fluorimetric determination of 7-hydroxycumarin 
(Aitio 1978). Testosterone hydroxylase (Longo et al. 
1991) and the all-trans-retinal oxidase (Zhang et al. 
1998; Wang et al. 2007) were determined by HPLC as 
previously reported. Astemizole O-demethylation and 
diclofenac hydroxylation were performed as previously 
described by Matsumoto et al. (2003) and Tang et al. 
(2000), respectively.
Arachidonic acid incubations
The reaction volume was 1 ml and it contained 100 mM 
phosphate buffer (pH 7.4), 10 μM arachidonic acid (AA), 
1 mM NADPH, and a CYP2J reconstituted system which 
consisted of 60 μg DLPC, 100 pmol of purified sheep 
CYP2J and 300 pmol of NADPH CYP reductase. The 
CYP2J reductase system was reconstituted by leaving 
the mixture at room temperature for 40 min before the 
addition of arachidonic acid and NADPH. Reactions were 
incubated for 30 or 60 min. at 37°C. The above conditions 
were repeated with boiled purified sheep CYP2J to use as 
a blank. For a positive control, incubations were repeated 
as above except 500 μg of sheep liver microsomes were 
used instead of the CYP2J reconstituted system and using 
boiled liver microsomes as a blank.
All reactions were stopped by acidifying to pH 4.5 with 
acetic acid followed by the addition of 500 pg of 11(12)-
EET-d8, 12-HETE-d8, and 11,12-DiHETrE-d11 to be used 
as internal standards. Each was then extracted with 2 vols 
of ethyl acetate twice, dried under nitrogen, reconstituted 
in 200 μl methanol, and stored at −80 C until LC/MS/MS 
analysis.
LC/MS/MS analysis
Eicosanoid identification and quantification was per-
formed with a Q-trap 3200 linear ion trap quadrupole 
LC/MS/MS equipped with a Turbo V ion source oper-
ated in negative electrospray mode (Applied Biosystems, 
Foster City, CA, USA). Extracted samples were suspended 
in 10 μl of methanol and injected into the HPLC via an 
Agilent 1200 standard series autosampler equipped with 
a thermostat set at 4°C (Agilent Technologies, Santa Clara, 
CA, USA). The HPLC component consisted of an Agilent 
1100 series binary gradient pump equipped with an 
Eclipse plus C18 (50 × 4.6 mm, 1.8 μm) column (Agilent 
Technologies). The column was eluted at a flow rate of 
0.500 ml min−1 with 100% mobile phase A (methanol/
water/acetic acid (60:40:0.01, v/v/v) from zero to 2 min 
and a gradient increasing to 100% B (100% methanol) at 
13 min. Multiple reaction monitoring (MRM) was used 
with a dwell time of 25 or 50 ms for each compound, with 
source parameters: ion spray voltage, −4500 V; curtain 
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gas, 40 U; ion source gas flow rate 1, 65 U and 2, 50 U; and 
temperature of 600°C. Synthetic standards were used to 
obtain standard curves (5–500 pg) for each eicosanoid 
(linear regression R2 > 0.99) and internal standard.
Eicosanoid values are expressed at pmol min−1 for the 
CYP2J reactions, and pmol mg−1 protein min−1 for liver 
reactions. Corresponding blank value averages (n = 2) 
were subtracted from incubation values. The arachidonic 
acid starting material was also analysed by LC/MS/MS 
for auto-oxidative products and these values were sub-
tracted from all incubations including the blanks.
Results and discussion
Gene cloning and sequence analysis
Using a PCR approach followed by RACE, a full-length 
CYP2J cDNA of 1628 bp was isolated from the sheep liver. 
The identified cDNA contained an open reading frame 
of 1506 bp, flanked by initiation (ATG) and termination 
(TGA) codons. That encoded a 502 amino acid polypep-
tide, as reported for the human CYP2J2 and rat CYP2J3 
(Scarborough et al. 1999), with a calculated molecular 
mass of 57 857 Da (Figure 2). The amino acid sequence of 
sheep CYP2J contained a putative heme-binding peptide 
(F S I G K R M C L G E Q L A) positioned between 441 and 
454 amino acid residues. The invariant cysteine responsi-
ble for heme binding, at position 448, and the other con-
served residues for any CYP are underlined. Moreover, 
in this putative amino acid sequence, it was possible to 
identify a proline-rich motif between positions 41 and 
51, which are important to anchor the protein to the 
endoplasmic reticular membrane. A comparison with 
the deduced amino acid sequence of the sheep CYP2J 
with that of other CYP2 families showed a homology of 
45–50%, whereas with respect to members of the CYP2J 
subfamily reported in the Gene Bank database (CYP2J1, 
various CYP2J2, CYP2J3, CYP2J4, CYP2J5, CYP2J6, 
CYP2J9) it was of 68–82% (Table 2). The highest homology 
was with Macaca fascicularis CYP2J2 (82%), Bos taurus 
and Homo sapiens CYP2J2 (80%). Gotoh (1992) predicted 
that the amino acid sequences of substrate recognition 
sites (SRSs) within CYPs should be more variable than 
the sequence of the rest of protein due to adaptive evolu-
tion. A comparison of the sheep CYP2J SRSs, as a guide 
to examine the function with those of other CYP2Js, 
revealed a comprehensively high homology and a com-
plete sequence share (100%) with the SRS2 and SRS4 of 
Canis familiaris, the SRS5 of Rattus norvegicus, and with 
the heme region of Bos taurus (Table 3). The alignment 
of SRS amino acid sequences also demonstrated that the 
SRS1 of sheep CYP2J has, as expected (Scarborough et al. 
1999), the lowest amino acid homology among SRSs of 
other CYP2J.
Tissue distribution of CYP2J mRNA
RT-PCR experiments and specific primers examined the 
tissue distribution of sheep CYP2J mRNA. As shown in 
Figure 3, a cDNA fragment of the predicted size (378 bp) 
was amplified from the RNA extracted from twelve tis-
sues of adult sheep (cortex, olfactory mucosa, respiratory 
mucosa, bronchi, lung, spleen, small intestine, heart, liver, 
kidney, aorta, and pulmonary artery). The sequences of 
all the fragments isolated from the extrahepatic tissues 
showed a perfect identity with that of liver. Thus, the 
CYP2J2 gene is expressed in all the tissues examined and 
particularly in the liver, where a more intense band was 
observed.
Heterologous expression of CYP2J in Escherichia coli
The native coding region of sheep CYP2J was inserted 
in the pCR4Blunt vector and used as a template for the 
introduction of the MALLLV and His-tag modification. 
The two fragments were sub-cloned in the pCR4Blunt 
vector. Restriction digestions accurately screened the 
many clones obtained and the positive clones were 
sequenced to test the correct insertion of the N-terminal 
and C-terminal modifications. The complete sequence 
of the modified CYP2J was recomposed directly in the 
pCWOri+ expression vector, which was transfected in 
E. coli DH5α as a host for the expression experiments. 
The membranes obtained from E. coli showed the pres-
ence of a functional cytochrome P450 as demonstrated 
by the CO-difference spectra that showed a maximum 
at 450 nm and a minor peak at 420 nm (Figure 4). 
The expression level of CYP2J was about 17 nmol l−1. 
Membranes were solubilized in a buffer containing the 
detergent CHAPS (1% v/v) and charged on an Ni-NTA 
agarose resin that presented high affinity for the four 
histidine tail, as described in the Materials and Methods 
section. The CYP2J was eluted as a single protein band, 
dialysed and collected for enzymatic characterization. 
As shown in Figure 5, this simple chromatographic step 
produced a substantially purified protein with a specific 
P450 content of 5.3 nmol mg−1 protein and a total yield 
of about 34% (Table 4). The absolute spectrum (Figure 6) 
of CYP2J had a Soret maximum at 422 nm and two minor 
peaks at 540 and 576 nm, indicative of a dominant low 
spin state, as reported for the rabbit CYP2J1 (Ichihara 
et al. 1985).
Tissue expression of CYP2J protein
Western blot assay (Figure 7) using polyclonal antibodies 
anti-human CYP2J2 showed a cross-reactive band with a 
molecular weight of about 55 kDa, in agreement with the 
calculated molecular weight of the purified recombinant 
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protein (56 727 Da), indicative of isolation of the sheep 
CYP2J.
Anti-human CYP2J2 IgG recognized a discrete band, 
although at a different extent, in CHAPS-solubilized 
microsomes from cortex, intestine, and spleen of sheep. 
At variance, these antibodies recognized in the liver 
and kidney solubilized microsomes at least two protein 
bands indicative of cross-reactivity with other CYPs or 
Figure 2. Nucleotide and deduced amino acid sequence of sheep CYP2J. The putative initial ATG start codon and the TGA stop codon are shown; 
the heme region is boxed; and the six putative SRS regions are underlined.
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the presence of more than one CYP2J. Further work will 
be necessary to determine if these sheep tissues contain 
multiple CYP2J isoforms.
Enzymatic characterization
Many known substrates of mammalian CYP2Js 
(Scarborough et al. 1999) were tested to determine the 
catalytic properties of the purified enzyme. The activi-
ties of CYP2J were carried out using a reconstituted 
system containing P450 reductase and cofactors as 
described in the Materials and Methods section. The 
purified CYP2J actively catalysed the oxidation of all-
trans-retinal with a rate of 40 pmol min−1 nmol−1 CYP 
in agreement with the data of rat CYP2J4 (Zhang et al. 
1998) and N-demethylation of aminopyrine with a rate of 
2.54 nmol min−1 nmol−1 CYP, as reported for the CYP2J1 
(Ichihara et al. 1985). On the contrary, despite multiple 
attempts and prolonged incubations, the recombinant 
sheep enzyme, unlike human CYP2J2 (Scarborough 
et al. 1999; Matsumoto et al. 2003), was inactive in the 
oxidation of aniline, testosterone, 7-ethoxycoumarin, 
diclofenac, and astemizole.
Arachidonic acid metabolism
To ascertain further the catalytic properties of recom-
binant CYP2J, this enzyme was incubated with arachi-
donic acid in a reconstituted system, as described in 
the Material and Methods section. CYP2J metabolized 
AA with a catalytic turnover of 10.3 pmol of products 
formed nmol−1 CYP min−1. The major products formed 
were 20-HETE, 19-HETE, and 18-HETE, which repre-
sented 86.1% of total metabolites. The EETs (14,15-EET, 
11,12-EET, 8,9-EET, and 5,6-EET) were formed in lower 
amounts (13.9% of the total). Thus, sheep CYP2J resulted 
to be predominantly an AA hydroxylase rather than an 
AA epoxygenase in keeping with mouse CYP2J9 (Qu 
et al. 2001) and rat CYP2J3 (Wu et al. 1997), but not with 
human CYP2J2 (Wu et al. 1996).
Regiochemical analysis of CYP2J-derived EETs (Table 5) 
revealed a preference for epoxidation at 14,15-double 
bond (44% of total EETs) followed by epoxidation at 8,9-, 
11,12-, and 5,6-double bonds (32.2%, 17.2%, and 6.3% of 
the total EET products, respectively). This EET regiose-
lectivity profile of sheep CYP2J is quite similar to that of 
human CYP2J2 (Wu et al. 1996) rather than that of mouse 
CYP2J9 (Qu et al. 2001).
Considering the regiochemical analysis of CYP2J-
derived HETEs (Table 5), in addition to the prominent 
formation of 19-HETE following by a minor amount of 
Table 2. Nucleotide and amino acid sequence identity between sheep 
CYP2J and CYP2J of other mammals.
Species
Nucleic acid Aminoacid
% identity % identity
2J2 Macaca Fascicularis 82 82
2J2 Bos taurus 85 80
2J2 Homo sapiens 80 80
2J2 Canis familiaris 83 79
2J1 Oryctolagus cuniculus 79 74
2J4 Rattus norvegicus 76 72
2J6 Mus musculus 76 73
2J3 Rattus norvegicus 76 69
2J5 Mus musculus 76 68
2J9 Mus musculus 75 69
Table 3. Sequence comparison (%) between sheep CYP2J and other mammalian orthologues at the substrate recognition sites (SRS 1-6) and 
heme binding domain.
Domain Ovis aries aa residues in CYP2J 2J2 Homo s. 2J2 Canis f. 2J2 Bos t. 2J2 Macaca f. 2J4 Rattus n.
Srs 1 109-131 72 86 50 77 50
Srs 2 211-219 88 100 88 88 88
Srs 3 247-254 78 66 66 88 66
Srs 4 301-318 94 100 88 94 94
Srs 5 373-383 91 91 82 91 100
Srs 6 481-488 62 75 62 75 62
Heme 441-454 93 86 100 93 86
Percentage of identity with the sheep sequence.
Sheep CYP2J
β-actin
Lu PACX OM RM Br Spl SI H Li K A
Figure 3. RT-PCR analysis of CYP2J mRNA in various organs of control sheep: cortex (Cx), olfactory mucosa (OM), respiratory mucosa (RM), 
bronchi (Br), lung (Lu), heart (H), spleen (Spl), small intestine (SI), liver (Li), kidney (K), aorta (A), and pulmonary artery (PA). PCR products were 
separated by electrophoresis on agarose gel and stained with ethidium bromide.
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20-HETE as found with mouse CYP2J9 and rat CYP2J3 
(Qu et al. 2001; Wu et al. 1997), a significant production 
of 18-HETE was also observed which was not previously 
reported for other CYP2J enzymes.
Like the recombinant CYP2J, sheep liver microsomes 
showed both AA epoxygenase and hydroxylase activi-
ties. However, with microsomes, unlike the recombinant 
CYP2J, the formation rate of 14,15-, 11,12-, 8,9-, and 
5,6-diydroxyeicosatrienoic acids (DHETs), as stable 
hydration products of corresponding EETs, was higher 
(46.7 pmol min−1 mg−1 protein) than that (33.2 pmol 
min−1 mg−1 protein) of HETEs (20-HETE, 19-HETE, and 
18-HETE) in agreement with what has been found in the 
human liver (Zeldin et al. 1996). In addition to this differ-
ence, between the AA oxidation by recombinant CYP2J 
55 KDa
Figure 5. Gel electrophoresis of Escherichia coli membranes at various 
stages of CYP2J purification. Lanes 1, membrane fraction; 2, CHAPS-
solubilized membranes; and 3, fraction eluted from an Ni-NTA agar-
ose column. Gel was visualized by Coomassie Brilliant Blue staining.
Table 4. Purification of sheep CYP2J from E. coli membranes.
Fraction Protein Content (mg/L) Total CYP (nmol/L) Specific content (nmol/mg prot) Yield (%)
E. coli membranes 119 17.5 0.14 100
Solubilized membranes 42 14 0.33 81
Ni-NTA Agarose eluate 1.1 5.9 5.3 34
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Figure 6. Absolute spectra of purified CYP2J in 100 mM potassium 
phosphate buffer, pH 7.2, 20% glycerol, 0.1 mM EDTA.
CYP2J K Spl Li H CxSI
Figure 7. Immunoblotting analysis of CYP2J in sheep tissues. Purified 
recombinant CYP2J (0.5 pmol) and CHAPS-solubilized microsomes 
from 5 μg of liver (Li), 40 μg of cortex (Cx), heart (H), spleen (Spl), kid-
ney (K), and small intestine (SI) were subjected to SDS-PAGE, trans-
ferred electrophoretically to a nitrocellulose membrane, and probed 
with polyclonal antibodies for anti-human CYP2J2.
Table 5. Regiochemical composition of EETs and HETEs produced by 
recombinant CYP2J and sheep liver microsomes.
Regioisomer
Distribution (% of total EETs / DHETs)
CYP2J microsomes
14,15-EET 44 51
11,12-EET 17.5 21.2
8,9-EET 32.2 21.8
5,6-EET 6.3 6
Regioisomer
Distribution (% of total EETs / DHETs)
CYP2J microsomes
20-HETE 16.9 34.9
19-HETE 53.9 30.4
18-HETE 29.2 34.7
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Figure 4. CO-reduced difference spectra of CHAPS-solubilized 
sheep CYP2J from Escherichia coli. The spectra was recorded in 
300 mM potassium phosphate buffer, pH 7.4, 20% glycerol, 1% 
CHAPS.
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and microsomes, a different distribution of DHETs and 
HETEs was also observed (Table 5). These results indi-
cate that CYP isoforms, other than CYP2J, present in the 
sheep liver microsomes, especially the CYP1A, CYP2C, 
and CYP4A abundant and catalytically active towards AA 
(Capdevilla et al. 1990; Zeldin et al. 1996; Scarborough 
et al. 1999), may contribute substantially to establish this 
different regioselectivity.
In conclusion, we have cloned the sheep CYP2J gene, 
have described its expression in E. coli, and isolated the 
protein in a functional form by a simplified chroma-
tographic technique. The purified CYP2J enzyme was 
active in the metabolism, among others, of AA leading 
to the regioselective formation of four EETs and three 
HETEs.
Given the important CYP2J functional role in the vas-
cular tissues of humans and rodents, the obtained infor-
mation on sheep CYP2J may be of utility for the study 
of cardiovascular disease and hypertension in this large 
animal model.
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